Mictoryl® Pediatric (propiverine hydrochloride) now covered by several public drug plans to treat symptoms associated with overactive bladder Read more >
Duchesnay Expands its Women’s Health Product Portfolio with Acquisition of Osphena® from Shionogi Inc. Read more >
Duchesnay Inc. is pleased to announce that Health Canada has granted market authorization for Mictoryl®/Mictoryl® Pediatric Read more >
Duchesnay Summarizes Comprehensive Body of Evidence for Most Studied Morning Sickness Drug Worldwide – Over 40 years of clinical experience, 16 cohort studies, two meta-analyses support regulatory approvals and guidelines – Read more >
Duchesnay donates $12,000 to Moisson Laurentides, surpassing our 2015 contribution of $10,000 Read more >
